These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26854716)

  • 1. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
    Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
    Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
    Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
    Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
    Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
    Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
    Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.
    Bortolin MT; Tedeschi R; Bidoli E; Furlan C; Basaglia G; Minatel E; Gobitti C; Franchin G; Trovò M; De Paoli P
    Biomarkers; 2015; 20(6-7):422-8. PubMed ID: 26526078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.
    Ezzeldin N; El-Lebedy D; Hassan M; Shalaby AO; Hussein SAM; Gharib AM; Hamdy G; Mohammed AM; Ramadan A; Sobeih ME
    J Egypt Natl Canc Inst; 2024 Jun; 36(1):21. PubMed ID: 38880832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
    Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
    J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Winther-Larsen A; Demuth C; Fledelius J; Madsen AT; Hjorthaug K; Meldgaard P; Sorensen BS
    Br J Cancer; 2017 Aug; 117(5):704-709. PubMed ID: 28683468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules.
    Chen C; Huang X; Yin W; Peng M; Wu F; Wu X; Tang J; Chen M; Wang X; Hulbert A; Brock MV; Liu W; Herman JG; Yu F
    Clin Epigenetics; 2020 Mar; 12(1):39. PubMed ID: 32138766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
    Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases.
    Fan L; Sha J; Teng J; Li D; Wang C; Xia Q; Chen H; Su B; Qi H
    Mol Diagn Ther; 2018 Aug; 22(4):493-502. PubMed ID: 29922886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
    Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
    Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.
    Du YZ; Gu XH; Li L; Gao F
    J Surg Oncol; 2011 Dec; 104(7):836-40. PubMed ID: 21656524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease.
    Schmidt B; Weickmann S; Witt C; Fleischhacker M
    Ann N Y Acad Sci; 2008 Aug; 1137():207-13. PubMed ID: 18837948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.